27 patents
Utility
Methods and compositions for treatment of epileptic disorders
7 Nov 23
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew During
Filed: 6 Apr 23
Utility
Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, attention deficit hyperactivity disorder and addiction
3 Oct 23
Methods of treating tinnitus, acute sensorineural hearing loss, Meniere's disease, Tourette's syndrome, ADHD or addiction with (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid or a pharmaceutically acceptable salt thereof are provided.
Matthew During
Filed: 17 Apr 20
Utility
Use of MIR101 or MIR128 in the treatment of seizure disorders
19 Sep 23
Methods of treating a seizure disorder in a patient in need thereof are provided which include delivering to the patient an effective amount of a composition that increases the level of microRNA-101 molecules in brain cells of the patient.
Matthew During
Filed: 17 Nov 20
Utility
Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
4 Jul 23
Treatment of non 24 sleep wake disorder using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew During
Filed: 17 Dec 19
Utility
Use of (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
30 May 23
Methods and compositions for use treating Fragile X syndrome, Angelman syndrome, Fragile X-associated tremor/ataxia syndrome, Autism Spectrum Disorder, Asperger's syndrome, Pervasive developmental disorder not otherwise characterized, Childhood Disintegrative Disorder, Williams syndrome, or Jacobsen syndrome with a compound of Formula 1 as described herein, (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid, or vagabatrin, or pharmaceutically acceptable salts of any of the foregoing, are provided.
Matthew During, Brett Abrahams
Filed: 16 Oct 20
Utility
Methods and compositions for treatment of epileptic disorders
26 Jul 22
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew During
Filed: 17 Sep 20
Utility
Gaboxadol for therapeutic treatment of 1p36 deletion syndrome
21 Jun 22
Methods and pharmaceutical compositions containing gaboxadol or a pharmaceutically acceptable salt thereof for treating 1p36 deletion syndrome are provided.
Matthew During
Filed: 18 Dec 20
Utility
Use of gaboxadol in the treatment of diabetes and related conditions
5 Apr 22
Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease.
Matthew During
Filed: 8 Oct 20
Utility
Methods for treating aggression associated with Alzheimer's disease
22 Mar 22
Methods of treating aggression associated with Alzheimer's Disease including administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient.
Matthew During
Filed: 29 Jun 18
Utility
Use of MIR-92A or MIR-145 in the treatment of Angelman syndrome
28 Sep 21
Expression of micoRNAs that negatively regulate the activity of the SNHG14 gene for can be used in treatment of Angelman Syndrome.
Matthew During
Filed: 7 Jul 20
Utility
Methods of treating developmental disorders with gaboxadol
24 Aug 21
Methods of treating developmental disorders such as Angelman syndrome, Fragile X syndrome, Fragile X-associated tremor/ataxia syndrome (FXTAS), Autistic Spectrum Disorder, Autism, Asperger's syndrome, pervasive developmental disorder, Childhood Disintegrative Disorder, Rett syndrome, Lanau-Kleffner Syndrome, Prader-Willi Syndrome, Tardive Dyskinesia, and/or Williams Syndrome with gaboxadol or a pharmaceutically acceptable salt thereof are provided.
Matthew During
Filed: 17 Dec 18
Utility
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
17 Aug 21
Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew During
Filed: 20 Aug 20
Utility
Methods of treating developmental disorders and/or seizure disorders with etifoxine
23 Feb 21
Methods of treating developmental disorders and/or seizure disorders with etifoxine, a deuterated analog of etifoxine, or a pharmaceutically acceptable salt, solvate, or prodrug thereof are provided.
Matthew During
Filed: 13 Aug 19
Utility
Use of MIR101 or MIR128 in the treatment of seizure disorders
21 Dec 20
Methods of treating a seizure disorder in a patient in need thereof are provided which include delivering to the patient an effective amount of a composition that increases the level of microRNA-101 molecules in brain cells of the patient.
Matthew During
Filed: 5 Dec 18
Utility
Use of MIR101 or MIR128 in the treatment of seizure disorders
16 Nov 20
Methods of treating a seizure disorder in a patient in need thereof are provided which include delivering to the patient an effective amount of a composition that increases the level of microRNA-101 molecules in brain cells of the patient.
Matthew During
Filed: 5 Dec 18
Utility
Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-l-carboxylic acid and related compounds, (1s,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders
26 Oct 20
Methods and compositions for use treating Fragile X syndrome, Angelman syndrome, Fragile X-associated tremor/ataxia syndrome, Autism Spectrum Disorder, Asperger's syndrome, Pervasive developmental disorder not otherwise characterized, Childhood Disintegrative Disorder, Williams syndrome, or Jacobsen syndrome with a compound of Formula 1 as described herein, (S)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid, (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid, or vagabatrin, or pharmaceutically acceptable salts of any of the foregoing, are provided.
Matthew During, Brett Abrahams
Filed: 6 Jun 19
Utility
Use of Gaboxadol in the treatment of diabetes and related conditions
26 Oct 20
Methods and compositions for treating a metabolic disease include administering gaboxadol or a pharmaceutically acceptable salt thereof to a patient diagnosed with a metabolic disease.
Matthew During
Filed: 1 Aug 18
Utility
Methods and compositions for treatment of epileptic disorders
12 Oct 20
Use of allosteric modulators and/or gaboxadol for the treatment of epileptic disorders in a subject in need thereof.
Matthew During
Filed: 12 Feb 20
Utility
Methods of treating developmental encephalopathies
7 Sep 20
Methods of treating developmental encephalopathies by administering compositions including ketamine, norketamine, or other derivatives of ketamine, or a pharmaceutically acceptable salt of any of the foregoing, are provided.
Matthew During
Filed: 11 Apr 18
Utility
Use of gaboxadol for the treatment of Tourette syndrome, tics and stuttering
7 Sep 20
Treatment of Tourette syndrome using gaboxadol or a pharmaceutically acceptable salt thereof is provided.
Matthew During
Filed: 19 Sep 19